Wang Ren, Lian Jie, Wang Xin, Pang Xiangyi, Xu Benjie, Tang Shuli, Shao Jiayue, Lu Haibo
Department of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Front Oncol. 2023 Mar 3;13:1033154. doi: 10.3389/fonc.2023.1033154. eCollection 2023.
This study aims to comprehensively summarize the colorectal survival rate in China. Method: In PubMed and Web of Science, keywords such as "colorectal cancer", "survival" and "China" were used to search literatures in the past 10 years. Random effect models were selected to summarize 1-year, 3-year, and 5-year survival rates, and meta-regression and subgroup analyses were performed on the included studies.
A total of 16 retrospective and prospective studies providing survival rates for colorectal cancer in China were included. The 1-year, 3-year, and 5-year survival rates of colorectal cancer in China were 0.79, 0.72 and 0.62, respectively. In the included studies, the 5-year survival rates of stage I (5474 cases), stage II (9215 cases), stage III (8048 cases), and stage IV (4199 cases) colorectal cancer patients were 0.85, 0.81, 0.57 and 0.30, respectively. Among them, the 5-year survival rates of colorectal cancer were 0.82, 0.76, 0.71, 0.67, 0.66, 0.65 and 0.63 in Tianjin, Beijing, Guangdong, Shandong, Liaoning, Zhejiang and Shanghai, respectively.
The 5-year survival rate in China is close to that of most European countries, but still lower than Japan and South Korea, and the gap is gradually narrowing. Region, stage, differentiation, pathological type, and surgical approach can affect 5-year survival in colorectal cancer.
https://www.crd.york.ac.uk/prospero/ identifier, CRD42022357789.
本研究旨在全面总结中国结直肠癌的生存率。方法:在PubMed和Web of Science中,使用“结直肠癌”“生存率”和“中国”等关键词检索过去10年的文献。选择随机效应模型总结1年、3年和5年生存率,并对纳入研究进行Meta回归和亚组分析。
共纳入16项提供中国结直肠癌生存率的回顾性和前瞻性研究。中国结直肠癌的1年、3年和5年生存率分别为0.79、0.72和0.62。在纳入研究中,I期(5474例)、II期(9215例)、III期(8048例)和IV期(4199例)结直肠癌患者的5年生存率分别为0.85、0.81、0.57和0.30。其中,天津、北京、广东、山东、辽宁、浙江和上海的结直肠癌5年生存率分别为0.82、0.76、0.71、0.67、0.66、0.65和0.63。
中国的5年生存率与大多数欧洲国家相近,但仍低于日本和韩国,且差距正在逐渐缩小。地区、分期、分化程度、病理类型和手术方式可影响结直肠癌的5年生存率。